Primary mediastinal large B-cell lymphoma.

Abstract:

:Primary mediastinal B-cell lymphoma (PMBCL) is a relatively rare lymphoma subtype affecting mainly young adults. Its molecular signature and clinical features resemble classical Hodgkin lymphoma. The optimal chemotherapy for this lymphoma subtype has not been established. The addition of rituximab to anthracycline based chemotherapy improved response rates and survival. Many centers use R-CHOP as standard treatment, but the role of the intensified regimens and consolidation radiotherapy has to be clarified. Recent data coming from retrospective analyses and an ongoing prospective study addressing the problem of consolidation radiotherapy will help to better identify risk groups and apply risk-adapted and effective treatment strategies. The latest research has helped to understand molecular mechanisms of PMBCL pathogenesis and indicated targets of directed therapy for the future.

journal_name

Curr Hematol Malig Rep

authors

Dabrowska-Iwanicka A,Walewski JA

doi

10.1007/s11899-014-0219-0

subject

Has Abstract

pub_date

2014-09-01 00:00:00

pages

273-83

issue

3

eissn

1558-8211

issn

1558-822X

journal_volume

9

pub_type

杂志文章
  • Recognizing unusual manifestations of Hodgkin lymphoma.

    abstract::Hodgkin lymphoma (HL) is a rare malignancy of the lymphatic system that is curable in at least 80 % of patients. Although patients usually present with painless lymphadenopathy, a variety of systemic and organ-specific syndromes may also exist in relation to HL. These syndromes may develop before, during, or after the...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-012-0131-4

    authors: Barber NA,Bierman PJ

    更新日期:2012-09-01 00:00:00

  • Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.

    abstract::Multiple myeloma is a disorder of terminally differentiated plasma cells, characterized by immune dysfunction, deregulated signaling within the bone marrow stromal compartment, and a microenvironment that fosters immunosuppression. Immunomodulatory techniques, such as allogeneic hematopoietic stem cell transplant (all...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-015-0283-0

    authors: Karp Leaf R,Cho HJ,Avigan D

    更新日期:2015-12-01 00:00:00

  • Social Media and Myeloproliferative Neoplasms (MPN)--Focus on Twitter and the Development of a Disease-specific Community: #MPNSM.

    abstract::The advent of social media has led to the ability for individuals all over the world to communicate with each other, in real time, about mutual topics of interest in an unprecedented manner. Recently, the use of social media has increased among people interested in healthcare and medical research, particularly in the ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-015-0287-9

    authors: Pemmaraju N,Gupta V,Mesa R,Thompson MA

    更新日期:2015-12-01 00:00:00

  • Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it?

    abstract::Acute myeloid leukemia (AML) is a very heterogeneous disease. Prognosis is related not only to intrinsic characteristics such as cytogenetics and molecular markers, but also the patient's ability to tolerate therapy, and treatment response. Allogeneic stem cell transplantation (allo-HCT) has been traditionally indicat...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-014-0207-4

    authors: Lekakis LJ,Cooper BW,de Lima MG

    更新日期:2014-06-01 00:00:00

  • Oral Chemotherapy in Patients with Hematological Malignancies-Care Process, Pharmacoeconomic and Policy Implications.

    abstract::Patients with hematologic malignancies are increasing being prescribed oral anticancer medications (OAMs) and/or biologics. These newer targeted OAMs are associated with a host of practical and pharmacoeconomic implications for patients and healthcare providers. Issues such as safety, procurement challenges, and the n...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-016-0325-2

    authors: Betcher J,Dow E,Khera N

    更新日期:2016-08-01 00:00:00

  • Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy.

    abstract:PURPOSE OF REVIEW:CMV DNA polymerase inhibitors such as ganciclovir and foscarnet have dramatically reduced the burden of CMV infection in the HCT recipient. However, their use is often limited by toxicities and resistance. Agents with novel mechanisms and favorable toxicity profiles are critically needed. We review re...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-020-00557-6

    authors: Hakki M

    更新日期:2020-04-01 00:00:00

  • Correction to: Strategies for Predicting Response to Checkpoint Inhibitors.

    abstract::The original version of this article unfortunately contained a mistake. The conflict of interest statement was incorrect. The corrected statement is given below. ...

    journal_title:Current hematologic malignancy reports

    pub_type: 已发布勘误

    doi:10.1007/s11899-018-0488-0

    authors: Zappasodi R,Wolchok JD,Merghoub T

    更新日期:2019-02-01 00:00:00

  • Who Should Receive a Transplant for Acute Lymphoblastic Leukaemia?

    abstract::Allogeneic haematopoietic cell transplantation continues to be an important curative therapy for acute lymphoblastic leukaemia (ALL). Traditionally accepted indications for allografting adult ALL patients need reevaluation in light of outcomes with paediatric-like intensive regimens. Minimal residual disease status an...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-017-0371-4

    authors: Dhawan R,Marks DI

    更新日期:2017-04-01 00:00:00

  • New aspects of the treatment of chronic lymphocytic leukemia.

    abstract::Progress in the understanding of the biology of chronic lymphocytic leukemia and in the development of new and effective therapies has generated a shift in treatment paradigms within only a few years. Traditional chemotherapy agents such as alkylators or nucleoside analogs are rapidly being replaced by combination reg...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-006-0006-7

    authors: Faderl S,Wierda W,Keating MJ

    更新日期:2006-12-01 00:00:00

  • High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond.

    abstract::Allogeneic hematopoietic cell transplantation (HCT) has curative potential for patients with myelodysplastic syndromes (MDS), though with considerable nonrelapse mortality and morbidity. The International Prognostic Scoring System, despite its confines, remains a widely used tool guiding treatment decisions in MDS. Th...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-009-0035-0

    authors: Gergis U,Wissa U

    更新日期:2010-01-01 00:00:00

  • A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine.

    abstract:PURPOSE OF REVIEW:There are limited treatment options for relapsed/refractory classical Hodgkin lymphoma (cHL) patients who progress on brentuximab vedotin and programmed death-1 inhibitors. Camidanlumab Tesirine (Cami) is a new agent that has shown activity in multiply relapsed/refractory cHL patients. In this review,...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-021-00604-w

    authors: Epperla N,Hamadani M

    更新日期:2021-01-25 00:00:00

  • Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy.

    abstract::Mycosis fungoides (MF) and its leukemic variant, Sézary syndrome (SS), are malignancies of skin-homing T cells that comprise the majority of cutaneous T cell lymphomas (CTCL). Treatment of CTCL is limited and can be approached by skin-directed therapy or systemic therapy. Recent investigations into the pathogenesis of...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-015-0293-y

    authors: Chung CG,Poligone B

    更新日期:2015-12-01 00:00:00

  • The role of parenteral nutrition in acute leukemia.

    abstract::Patients with acute leukemia who undergo hematopoietic stem cell transplantation (HSCT) are susceptible to malnutrition caused by several factors including intensive cytotoxic therapy. This paper discusses the significance of malnutrition in these patients and provides an overview of nutrition therapy by the oral, ent...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-996-0007-6

    authors: Jacobson NB,Parekh N,Kalaycio M

    更新日期:2006-09-01 00:00:00

  • Frontline therapy in mantle cell lymphoma: the role of high-dose therapy and integration of new agents.

    abstract::Mantle cell lymphoma (MCL) is a unique lymphoma subtype comprising 6% to 8% of new lymphoma diagnoses. It is generally considered to be incurable with standard lymphoma therapies. The median overall survival (OS) is often reported to be 3 to 4 years, but more recent data suggest that the median OS may be longer than 5...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-009-0028-z

    authors: Kahl BS

    更新日期:2009-10-01 00:00:00

  • Treatment of immunoglobulin light chain amyloidosis.

    abstract::No therapy is uniformly effective in the management of immunoglobulin light chain amyloidosis (AL amyloidosis). Despite the common generalization, therapy is highly effective. Options available to patients with AL amyloidosis include high-dose therapy, but this is applicable to only about one fourth of patients. Thera...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-009-0013-6

    authors: Gertz MA,Zeldenrust SR

    更新日期:2009-04-01 00:00:00

  • Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making.

    abstract:PURPOSE OF REVIEW:Over the past two decades, the introduction of tyrosine kinase inhibitors (TKIs) has transformed the treatment of chronic myeloid leukemia (CML). With four agents currently approved for frontline use in chronic-phase (CP) disease, it follows that treatment decision-making has been rendered more challe...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-018-0449-7

    authors: Kennedy JA,Hobbs G

    更新日期:2018-06-01 00:00:00

  • Role of minimal residual disease evaluation in leukemia therapy.

    abstract::In patients with acute leukemia, measurements of minimal residual disease (MRD) provide unique information on response to treatment. The most useful currently available MRD assays are polymerase chain reaction amplification of fusion transcripts and rearranged antigen-receptor genes and flow cytometric detection of ab...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章

    doi:10.1007/s11899-008-0022-x

    authors: Campana D

    更新日期:2008-07-01 00:00:00

  • Chronic myelomonocytic leukemia prognostic classification and management: evidence base and current practice.

    abstract::Chronic myelomonocytic leukemia is a clonal malignancy of the ageing hematopoietic stem cell characterized by a biased differentiation leading to persistent monocytosis and inconstant hypersensitivity of myeloid progenitors to granulo-monocyte colony-stimulating factor (GM-CSF). Cytogenetic abnormalities identified in...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-014-0225-2

    authors: Selimoglu-Buet D,Solary E

    更新日期:2014-12-01 00:00:00

  • Targets, Toxins, and T Cells--a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas.

    abstract::The peripheral T cell lymphomas (PTCLs) are a heterogeneous group of neoplasms for which standardized treatment approaches remain elusive. A number of new therapeutic agents have become available, of which monoclonal antibodies (MAbs) represent a powerful tool for targeted treatment of PTCLs. Therapeutic MAbs vary in ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-015-0290-1

    authors: Hebb J,Kohrt H

    更新日期:2015-12-01 00:00:00

  • Frailty in Hematologic Malignancy.

    abstract:PURPOSE OF REVIEW:Older adults with hematologic malignancy are a growing demographic. Estimating risk of chemotherapy toxicity based on age alone is an unreliable estimate of quality of life, functional capacity, or risk of treatment complications. RECENT FINDINGS:Dedicated geriatric assessment tools can aid the clini...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-018-0454-x

    authors: Koll TT,Rosko AE

    更新日期:2018-06-01 00:00:00

  • Perspective on the role of haploidentical transplantation in the management of hematologic malignancies: why do it?

    abstract::Haploidentical hematopoietic stem cell transplantation (HSCT) using mismatched family member donors has historically been complicated by high rates of nonrelapse toxicity and the need for laboratory expertise in depleting grafts of T lymphocytes. Over the past decade, improvements in supportive care, the increased use...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-007-0027-x

    authors: Hale GA

    更新日期:2007-07-01 00:00:00

  • Navigating Ethical Practices in the Era of High Cost Hematology.

    abstract:PURPOSE OF REVIEW:In this review article, we will highlight ethical issues faced by hematologists due to a growing constellation of expensive diagnostics and therapeutics in hematology. We outline the important issues surrounding this topic including stakeholders, cost considerations, and various ethical challenges sur...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-020-00599-w

    authors: Ertz-Archambault N,Khera N

    更新日期:2020-10-01 00:00:00

  • Chemotherapy for patients with acute myeloid leukemia in first remission.

    abstract::Although the majority of patients with acute myeloid leukemia (AML) achieve a complete remission with induction chemotherapy, most will ultimately relapse. Therefore, the optimal postremission therapy for AML remains to be defined, and further improvements in treatment strategies are required. Clinical trials have dem...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-006-0021-8

    authors: Bradstock K

    更新日期:2006-06-01 00:00:00

  • Choosing Wisely® in Hematology: Have We Made a Difference?

    abstract:PURPOSE OF REVIEW:The Choosing Wisely® initiative, led by the American Board of Internal Medicine Foundation in collaboration with national professional medical societies, aims to help patients choose care that is essential, free from harm, and evidence-based. The American Society of Hematology has advocated practices ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-020-00593-2

    authors: Hilal T,Munoz J

    更新日期:2020-08-01 00:00:00

  • Twitter Use in the Hematopoietic Cell Transplantation Community.

    abstract:PURPOSE OF REVIEW:Social media has revolutionized the access and exchange of information in healthcare. The microblogging platform Twitter has been used by blood and marrow transplant physicians over the last several years with increasing enthusiasm. We review the adoption of Twitter in the transplant community and its...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-018-0434-1

    authors: Patel SS,Majhail NS

    更新日期:2018-02-01 00:00:00

  • The Future of Targeting FLT3 Activation in AML.

    abstract::Internal tandem duplications (ITD) and tyrosine-kinase domain (TKD) mutations of the FMS-like tyrosine-kinase 3 (FLT3) can be found in up to one third of patients with acute myeloid leukemia (AML) and confer a poor prognosis. First discovered 20 years ago, these mutations were identified as viable therapeutic targets,...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-017-0381-2

    authors: Leick MB,Levis MJ

    更新日期:2017-06-01 00:00:00

  • Assessing Quality of Care for the Myelodysplastic Syndromes.

    abstract::Measuring the quality of care for patients with chronic cancers is difficult, especially for heterogeneous malignancies such as the myelodysplastic syndromes (MDS). Recent work suggests that improvements may be needed in the quality of diagnostic, treatment, and end-of-life care for patients with these syndromes. More...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-016-0343-0

    authors: Frosch ZA,Abel GA

    更新日期:2016-12-01 00:00:00

  • Clostridium difficile: deleterious impact on hematopoietic stem cell transplantation.

    abstract::C. difficile infection (CDI), the most common cause of hospital-acquired diarrhea, is very frequent after hematopoietic stem cell transplantation (HSCT). Recent publications suggest it affects between 6 % and 20 % of HSCT recipients during the first year and is more common following allogeneic transplant (allo-HSCT). ...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-013-0193-y

    authors: Callejas-Díaz A,Gea-Banacloche JC

    更新日期:2014-03-01 00:00:00

  • Artificial Intelligence in Hematology: Current Challenges and Opportunities.

    abstract:PURPOSE OF REVIEW:Artificial intelligence (AI), and in particular its subcategory machine learning, is finding an increasing number of applications in medicine, driven in large part by an abundance of data and powerful, accessible tools that have made AI accessible to a larger circle of investigators. RECENT FINDINGS:...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-020-00575-4

    authors: Radakovich N,Nagy M,Nazha A

    更新日期:2020-06-01 00:00:00

  • Infant acute lymphoblastic leukemia: Lessons learned and future directions.

    abstract::Compared with acute lymphoblastic leukemia (ALL) in older children, ALL in infants has a dismal outcome because rearrangements of the mixed-lineage leukemia (MLL) gene occur in about 80% of these patients, leading to an aggressive type of leukemia. With most recent therapies, about 50% long-term event-free survival is...

    journal_title:Current hematologic malignancy reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11899-009-0023-4

    authors: Pieters R

    更新日期:2009-07-01 00:00:00